Corvus (CRVS) stock's soquelitinib shows early promise in PTCL & atopic dermatitis, but a $1.24B valuation may be ahead of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results